Evidence map›Paper›PMID 37804930›Full record

ArticleMatrix biology : journal of the International Society for Matrix Biology2023

Tissue inhibitors of metalloproteinases are proteolytic targets of matrix metalloproteinase 9.

Sasha Coates-Park, Carolyn Lazaroff, Sadeechya Gurung, Josh Rich, Alexandra Colladay, Maura O'Neill, Georgina S Butler, Christopher M Overall, William G Stetler-Stevenson, David Peeney

Open access · hybridAbstract read
In one paragraph

Article in Matrix biology : journal of the International Society for Matrix Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polymer science & technology (Washington, D.C.) · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. The TIMP protein family: diverse roles in pathophysiology.American journal of physiology. Cell physiology · 2024
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Sasha Coates-ParkExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.
Carolyn LazaroffExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States; Department of Orthopedics, Washington University in St. Louis School of Medicine, United States.
Sadeechya GurungExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.
Josh RichExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.
Alexandra ColladayExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.
Maura O'NeillProtein Characterization Laboratory, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, United States.
Georgina S ButlerCentre for Blood Research, Life Sciences Centre, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; Department of Oral Biological and Medical Science, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
Christopher M OverallCentre for Blood Research, Life Sciences Centre, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; Department of Oral Biological and Medical Science, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
William G Stetler-StevensonExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States.
David PeeneyExtracellular Matrix Pathology Section, Laboratory of Pathology, National Cancer Institute, National Institute of Health, Bethesda, MD, United States. Electronic address: david.peeney@nih.gov.
National Cancer Institute · USUniversity of British Columbia · CANational Institutes of Health · USWashington University in St. Louis · US

Funding

The Role of TIMPs in Cell Growth, Tumor Progression and MetastasisZIASC009179 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI STETLER-STEVENSON, WILLIAM · 2009 to 2024
$9.7M
Tissue Inhibitors of Metalloproteinases: Regulation of CZ01SC009179 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI STETLER-STEVENSON, WILLIAM G · 1996 to 2008
$3.4M
Intramural NIH HHS Z01 SC009179Intramural NIH HHS ZIA SC009179
6 · The paper itself

Abstract

Extracellular proteolysis and turnover are core processes of tissue homeostasis. The predominant matrix-degrading enzymes are members of the Matrix Metalloproteinase (MMP) family. MMPs extensively degrade core matrix components in addition to processing a range of other factors in the extracellular, plasma membrane, and intracellular compartments. The proteolytic activity of MMPs is modulated by the Tissue Inhibitors of Metalloproteinases (TIMPs), a family of four multi-functional matrisome proteins with extensively characterized MMP inhibitory functions. Thus, a well-regulated balance between MMP activity and TIMP levels has been described as critical for healthy tissue homeostasis, and this balance can be chronically disturbed in pathological processes. The relationship between MMPs and TIMPs is complex and lacks the constraints of a typical enzyme-inhibitor relationship due to secondary interactions between various MMPs (specifically gelatinases) and TIMP family members. We illustrate a new complexity in this system by describing how MMP9 can cleave members of the TIMP family when in molar excess. Proteolytic processing of TIMPs can generate functionally altered peptides with potentially novel attributes. We demonstrate here that all TIMPs are cleaved at their C-terminal tails by a molar excess of MMP9. This processing removes the N-glycosylation site for TIMP3 and prevents the TIMP2 interaction with latent proMMP2, a prerequisite for cell surface MMP14-mediated activation of proMMP2. TIMP2/4 are further cleaved producing ∼14 kDa N-terminal proteins linked to a smaller C-terminal domain through residual disulfide bridges. These cleaved TIMP2/4 complexes show perturbed MMP inhibitory activity, illustrating that MMP9 may bear a particularly prominent influence upon the TIMP:MMP balance in tissues.

Indexed as

Matrix Metalloproteinase 9Tissue Inhibitor of MetalloproteinasesGelatinasesProteinsProteolysisGelatinasesMatrix Metalloproteinase 9ProteinsTissue Inhibitor of MetalloproteinasesExtracellular matrixMatrisomeMMPTIMP

Identifiers

PMID37804930
PMCPMC10843048
OpenAlexW4387380992

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.